Established in September 2011, the Korea Drug Development Fund (KDDF), a consortium of three health-related Korean Ministries - the Ministry of Science and ICT; the Ministry of Trade, Industry, and Energy; and the Ministry of Health and Welfare - is a government-initiated drug development program, which aims to transform Korea into a global leader for new drug development and to enhance national competitiveness in the global arena.

KDDF focuses on building its own business portfolio and process that is essential to global drug development. We established a top-notch screening system for numerous research and development (R&D) projects, coupled with a successful milestone-based output management system. KDDF further materialized its innovation-driven portfolio management strategy through a newly introduced joint R&D program with global Big Pharma, the actual developers who aspire to commercialize early-stage assets, and continued to expand its support in the Research & Business Development (R&BD) field. Further, KDDF supports the drug development community with diverse resources and consulting services to enhance the value of their new drug projects.

KDDF places more priority on investing pipelines at an earlier stage of development as Korea is already being recognized for its excellent clinical research and drug development infrastructure, world-class researchers, hospitals, and facilities. We spur more aggressive investment to create new first-in-class products and attractive technologies and to pave the way for expediting earlier technology transfer and attempt to shorten the development process ceaselessly by investing in early novel treatment for global licensing-out opportunities at an early stage.

KDDF is an ideal partner that can address the so-called “bottleneck” in the new drug development phase. In order to effectively meet the challenges faced by local scientists and to create an ecosystem in which they feel comfortable performing long-term R&D, KDDF will come up with optimal solutions via a large pool of domestic and foreign experts who will form its consultation group.

KDDF passes on the world-class expertise in its consulting manpower and project management system to the whole industry circle. Since 2011, the fund has accumulated valuable know-how in drug development. It is imperative that the KDDF’s assets must be shared with all scientists working in the local healthcare and biopharmaceutical sector since these assets do not belong only to KDDF. With this in mind, every KDDF member will have more opportunities to meet with you and to share our knowledge actively.

KDDF, which is backed by a collaborative effort of three healthcare-related ministries for the first time in Korea, has supported all stages of drug development with brilliant achievements. With its vision to transform Korea into a global leader for new drug development, KDDF will endeavor to raise national competitiveness by sustaining the outcomes and achieving goals as an internationally recognized benchmark model.
We would appreciate your kind advice and innovative ideas at all times.

Thank you.

Sincerely,

Muk, Hyunsang
CEO
KDDF